Myriad Genetics, Inc.

Report azionario NasdaqGS:MYGN

Capitalizzazione di mercato: US$327.1m

Myriad Genetics Performance degli utili passati

Criteri Il passato verificati 0/6

Gli utili di Myriad Genetics sono diminuiti a un tasso medio annuo di -31.6%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 34.1%. I ricavi sono cresciuti crescere a un tasso medio annuo di 5.5%.

Informazioni chiave

-31.58%

Tasso di crescita degli utili

-28.03%

Tasso di crescita dell'EPS

Biotechs Crescita del settore17.04%
Tasso di crescita dei ricavi5.45%
Rendimento del capitale proprio-37.05%
Margine netto-13.96%
Ultimo aggiornamento sugli utili30 Jun 2026

Aggiornamenti sulle prestazioni recenti

Recent updates

Aggiornamento narrativa • Sep 03

MYGN: Payer Friction And Prenatal Weakness Will Pressure Turnaround Prospects

The analyst price target for Myriad Genetics has been cut to $2, with analysts pointing to weak Q2 results, reduced FY26 revenue guidance, payer friction in Hereditary Cancer Testing, slower Prenatal volume recovery, and questions about the current business model's path to profitability as key reasons for the lower fair value and future P/E assumptions. Analyst Commentary Recent Street research on Myriad Genetics has turned more cautious, with several bearish analysts cutting price targets into the US$2 to US$4 range and questioning how the current business model supports long term growth and profitability.
Aggiornamento narrativa • Aug 18

MYGN: Turnaround Will Rely On Stabilising Hereditary Cancer And Prenatal Testing

Analysts have cut their fair value estimate for Myriad Genetics from $10.00 to $5.45, reflecting lower price targets in the $3.00 to $4.00 range after the Q2 miss, reduced guidance, and ongoing concerns around execution and testing headwinds. Analyst Commentary Recent Street research on Myriad Genetics points to a reset in expectations after the Q2 update.
Aggiornamento narrativa • Aug 04

MYGN: Q2 Miss And Lower Guide Will Temper Turnaround Expectations

Analysts have trimmed their fair value estimate for Myriad Genetics to $3.00 from $4.00, reflecting updated views on slower revenue growth, modestly lower profit margins, a higher discount rate, and reduced future P/E assumptions following recent Q2 results and guidance updates. Analyst Commentary Recent research updates on Myriad Genetics point to a more cautious stance from several bearish analysts following the Q2 earnings release and guidance changes.
Seeking Alpha • Aug 01

Myriad Genetics: Strong Oncology Demand, But Monetization Breaks Down

Summary Myriad Genetics faces persistent reimbursement and pricing headwinds, despite stable oncology volumes and pipeline momentum, driving margin compression and revenue volatility. Management is executing the Ascend initiative, aiming to optimize the revenue cycle, automate claims, and improve payer engagement, with the potential for margin inflection by 2027 if successful. FY26 revenue guidance is tightened to $770–$790 million, with adjusted EBITDA guidance withdrawn, reflecting near-term uncertainty and limited visibility on operational improvements. I maintain a Hold rating, as the business remains a turnaround story; execution on reimbursement and revenue conversion is critical before upside can be realized. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 09

MYGN: New Cancer Test Data And AI Initiatives Will Support A Balanced Outlook

Analysts trimmed their price outlook for Myriad Genetics, lowering the implied fair value estimate from $8.12 to $6.25 as they recalibrated assumptions around revenue growth, profit margins, and future P/E expectations following recent research updates. What’s in the News for Myriad Genetics Myriad Genetics reported new large scale meta analysis data for its Prolaris Biopsy Test in localized prostate cancer, showing that the combined clinical risk score was significantly prognostic for distant metastasis and prostate cancer specific mortality across multiple risk groups and treatment strategies, based on 14 studies with data from more than 8,000 patients (source: Clinical Genitourinary Cancer publication).
Aggiornamento narrativa • Jun 25

MYGN: 2026 Turnaround Will Be Driven By Expanded Cancer Testing Reach

Analysts have trimmed their target on Myriad Genetics stock by $1, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What’s in the News for Myriad Genetics Expanded availability of the Precise MRD test to patients with breast, colorectal, and renal cancers in the U.S., targeting a population of more than 6 million individuals and providing personalized, whole genome sequencing based ctDNA monitoring across the cancer care continuum.
Aggiornamento narrativa • Jun 08

MYGN: 2026 Revenue Outlook And Lowered Multiple Will Pressure Sentiment

Analysts have modestly reduced their price target on Myriad Genetics by $1, citing updated assumptions around revenue growth, profitability and future P/E multiples reflected in recent research, including the TD Cowen report. What's in the News Myriad plans to present extensive data on its Precise MRD test across multiple solid tumor types, including interim outcomes from the MONSTAR-SCREEN-3 study.
Aggiornamento narrativa • May 25

MYGN: 2026 Turnaround Execution And Cancer Testing Expansion Will Drive Upside

The analyst price target for Myriad Genetics has been reset from $16.06 to $10.00 as analysts factor in lower Street targets around $6, updated assumptions for revenue growth and profit margins, and a revised future P/E closer to 6.3x. Analyst Commentary Recent Street research has generally moved toward more cautious price targets around US$6, but there are still some constructive signals that matter if you are looking at Myriad Genetics through a valuation and execution lens.
Aggiornamento narrativa • Apr 21

MYGN: 2026 Turnaround And Pipeline Milestones Will Keep Sentiment Cautious

Analyst price targets on Myriad Genetics have moved slightly lower, with recent cuts to $6 from $8 and $6.50, as analysts wait for clearer evidence of progress on the turnaround plan, pipeline milestones, and improved growth and profitability before shifting their stance. Analyst Commentary Recent Street research reflects a cautious stance on Myriad Genetics, with bearish analysts trimming price targets and highlighting execution and growth risks despite some operational positives.
Aggiornamento narrativa • Apr 05

MYGN: 2026 Turnaround Execution And Pipeline Delivery Will Sustain Bearish Caution

Analysts have trimmed their price targets on Myriad Genetics to a range of $6 to $7, reflecting caution around the pace of the turnaround and the need for clearer progress on growth, profitability and pipeline execution before taking a more constructive stance. Analyst Commentary Recent research updates point to a cautious tone, with several bearish analysts trimming price targets into the US$6 to US$7 range and maintaining neutral ratings.
Aggiornamento narrativa • Mar 21

MYGN: Turnaround Execution In 2026 Will Drive Continued Cautious Sentiment

The Street’s blended price target for Myriad Genetics has shifted lower into a $6 to $7 range as analysts factor in updated sector models, reiterated 2026 guidance, and the need for clearer progress on the company’s turnaround and profitability before becoming more constructive. Analyst Commentary Recent research updates show a clear tilt toward caution, with several bearish analysts trimming their valuation ranges for Myriad Genetics and keeping ratings in the middle of the scale rather than moving to a more positive stance.
Aggiornamento narrativa • Mar 06

MYGN: Turnaround Execution And 2026 Pipeline Milestones Will Drive Bearish Outlook

Analysts have trimmed their price targets on Myriad Genetics to a range of about $6 to $7, reflecting more cautious assumptions on growth and profitability even as they acknowledge recent results and the company’s ongoing turnaround efforts. Analyst Commentary Recent research updates show bearish analysts trimming price targets on Myriad Genetics into a tighter band around $6 to $7, signaling a more cautious stance on the stock even as they acknowledge operational progress.
Aggiornamento narrativa • Feb 19

MYGN: Rebased Outlook Weighs Execution Risks Against Upcoming MRD Commercialization Potential

Analysts have adjusted their outlook on Myriad Genetics, trimming the average price target to $7 from $9. They have also updated their assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E based on recent diagnostics sector research and expectations for solid results and 2026 guidance.
Articolo di analisi • Feb 13

Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding

To the annoyance of some shareholders, Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares are down a considerable 27% in the...
Aggiornamento narrativa • Feb 05

MYGN: Sector Fundamentals And New Diagnostics Partnerships Will Support A More Constructive Outlook

Analysts have lowered their price target on Myriad Genetics to $7 from $9, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, while still expecting solid diagnostics sector results and 2026 outlooks. Analyst Commentary Recent research on Myriad Genetics focuses on how the updated $7 price target lines up with expectations for the broader diagnostics group, where analysts still see solid sector results and 2026 outlooks supported by what they describe as strong fundamentals.
Articolo di analisi • Feb 04

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Aggiornamento narrativa • Jan 22

MYGN: Sector Strength And Expanded Cancer Testing Will Support Future Upside

Narrative Update Analysts have adjusted their view on Myriad Genetics, reflected in a higher fair value estimate from $14.33 to $16.06 as they weigh mixed price target moves in recent research and slightly different assumptions for growth, margins, and future P/E. Analyst Commentary Recent Street research on Myriad Genetics presents a mixed but informative picture, with some caution on price targets alongside more constructive adjustments that support the updated fair value estimate.
Aggiornamento narrativa • Jan 08

MYGN: Sector Strength And New Partnerships Will Support A More Constructive Outlook

Narrative Update The analyst price target for Myriad Genetics has shifted modestly lower, with a blended change of roughly $1 across recent moves to $7 and $8. Analysts are factoring in updated diagnostics sector expectations and revising their fair value estimates and P/E outlooks for the company.
Aggiornamento narrativa • Dec 24

MYGN: Rising Margin Visibility Will Support A More Constructive Bullish Outlook

Analysts have raised their price target on Myriad Genetics shares from $6.00 to $8.00, reflecting modest improvements in long term profit margin expectations and valuation assumptions, while maintaining a neutral overall outlook. Analyst Commentary Analyst commentary around the revised price target highlights a generally balanced view, with recognition of incremental progress offset by lingering execution and profitability concerns.
Aggiornamento narrativa • Dec 10

MYGN: Improved Earnings Visibility Will Shape Bullish Outlook

Analysts have modestly raised their price target on Myriad Genetics to $8 from $6, reflecting a slightly higher fair value estimate supported by improved forward price to earnings assumptions and a marginally higher discount rate that still preserves cautious revenue growth expectations. Analyst Commentary Analyst sentiment around Myriad Genetics remains balanced, with the higher price target reflecting modest improvements in forward expectations rather than a decisive shift in outlook.
Aggiornamento narrativa • Nov 26

MYGN: Breast Cancer Risk Collaboration And Margin Gains Will Shape Outlook

Narrative Update on Myriad Genetics Analysts have raised their price target for Myriad Genetics from $6 to $8, citing improved profit margins and modest revenue growth as key drivers for the upward revision. Analyst Commentary Analyst opinions about Myriad Genetics reflect a mix of optimism regarding the company's recent performance and continued caution around potential challenges.
Aggiornamento narrativa • Nov 12

MYGN: Expanded Cancer Testing Is Expected To Drive Future Gains

Narrative Update on Myriad Genetics Analysts have increased their price target for Myriad Genetics from $6 to $8. This adjustment reflects revised expectations based on updates to fair value assessments, discount rates, and future earnings metrics.
Aggiornamento narrativa • Oct 29

Adding Cancer Test Capabilities And Mental Health Data Will Support Long-Term Progress

Analysts have slightly raised their price target for Myriad Genetics to approximately $7.95 from $7.77 per share. They cited modest improvements in expected profit margins and updated assumptions around discount rates.
Aggiornamento narrativa • Oct 14

Expanding Oncology Testing And Genomic Profiling Will Widen Market Reach

Analysts have adjusted their price target for Myriad Genetics upward from $7.38 to $7.77, citing minor improvements in profit margin and future price-to-earnings expectations, even though revenue growth projections have been slightly reduced. What's in the News Myriad Genetics has formed a strategic partnership with SOPHiA GENETICS to develop and globally deploy a liquid biopsy companion diagnostic test for pharmaceutical companies, leveraging both companies' expertise and international networks (Strategic Alliances).
Articolo di analisi • Sep 30

Estimating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Key Insights Myriad Genetics' estimated fair value is US$8.13 based on 2 Stage Free Cash Flow to Equity Myriad...
Articolo di analisi • Aug 17

Myriad Genetics, Inc. (NASDAQ:MYGN) Held Back By Insufficient Growth Even After Shares Climb 28%

NasdaqGS:MYGN 1 Year Share Price vs Fair Value Explore Myriad Genetics's Fair Values from the Community and select...
Articolo di analisi • Jun 25

Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Those holding Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares would be relieved that the share price has rebounded 29% in...
Articolo di analisi • May 09

Lacklustre Performance Is Driving Myriad Genetics, Inc.'s (NASDAQ:MYGN) 48% Price Drop

To the annoyance of some shareholders, Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares are down a considerable 48% in the...
User avatar
Nuova narrativa • Mar 24

PATHOMIQ AI Partnership Will Expand Oncology And Women's Health

Strategic partnerships and investments in AI and women's health aim to enhance oncology offerings and capture larger market shares, driving revenue growth.
Articolo di analisi • Mar 16

Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31%

Myriad Genetics, Inc. ( NASDAQ:MYGN ) shareholders that were waiting for something to happen have been dealt a blow...
Articolo di analisi • Feb 26

Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results

There's been a notable change in appetite for Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares in the week since its annual...

Ripartizione dei ricavi e delle spese

Come Myriad Genetics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storico di utili e ricavi

NasdaqGS:MYGN Ricavi, spese e utili (USD Millions )
DataRicaviUtiliSpese G+ASpese di R&S
30 Jun 26807-113540106
31 Mar 26829-400538106
31 Dec 25825-366538107
30 Sep 25825-400549114
30 Jun 25833-395550114
31 Mar 25831-101555116
31 Dec 24838-127560113
30 Sep 24824-116563102
30 Jun 24802-15556098
31 Mar 24774-23556291
31 Dec 23753-26357389
30 Sep 23734-27458791
30 Jun 23699-24858188
31 Mar 23695-14655187
31 Dec 22678-11251585
30 Sep 22661-7744483
30 Jun 22672-1849481
31 Mar 22682-851380
31 Dec 21691-2753882
30 Sep 21684-5759980
30 Jun 21662-9754278
31 Mar 21566-14851476
31 Dec 20557-22450173
30 Sep 20598-19449974
30 Jun 20639-19950777
31 Mar 20761-14853981
31 Dec 19813-2654683
30 Sep 19835-1554786
30 Jun 19851555786
31 Mar 198302351283
31 Dec 187962647980
30 Sep 187675445174
30 Jun 1874413343571
31 Mar 1874913044472
31 Dec 1776312645971
30 Sep 1777110147273
30 Jun 177291744074
31 Mar 177573244675
31 Dec 167516341475
30 Sep 167489438573
30 Jun 1674111735971
31 Mar 1675712134970
31 Dec 1574710834969
30 Sep 157389535170

Guadagni di qualità: MYGN al momento non è redditizia.

Margine di profitto in crescita: MYGN al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: MYGN non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 31.6% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di MYGN nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: MYGN non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 64.6% ).

Rendimento del capitale proprio

ROE elevato: MYGN ha un Return on Equity negativo ( -37.05% ), in quanto al momento non è redditizio.

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/09/14 07:17
Prezzo dell'azione a fine giornata2026/09/14 00:00
Utili2026/06/30
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Myriad Genetics, Inc. è coperta da 38 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jack MeehanBarclays
Michael RyskinBofA Global Research
Lu LiBofA Global Research